AU2019243133B2 - Novel compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising same - Google Patents

Novel compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising same Download PDF

Info

Publication number
AU2019243133B2
AU2019243133B2 AU2019243133A AU2019243133A AU2019243133B2 AU 2019243133 B2 AU2019243133 B2 AU 2019243133B2 AU 2019243133 A AU2019243133 A AU 2019243133A AU 2019243133 A AU2019243133 A AU 2019243133A AU 2019243133 B2 AU2019243133 B2 AU 2019243133B2
Authority
AU
Australia
Prior art keywords
compound
ethanol
present
phenyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019243133A
Other languages
English (en)
Other versions
AU2019243133A1 (en
Inventor
Tae Hyun Bae
Srinivasrao GANIPISETTI
Chan Hoon Jung
Eui Jung Jung
Yong Tae Kwon
Su Ran Mun
Ki Woon Sung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
Seoul National University R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul National University R&DB Foundation filed Critical Seoul National University R&DB Foundation
Publication of AU2019243133A1 publication Critical patent/AU2019243133A1/en
Application granted granted Critical
Publication of AU2019243133B2 publication Critical patent/AU2019243133B2/en
Assigned to SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION reassignment SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION Request for Assignment Assignors: PROTECH CO., LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/60—Preparation of compounds containing amino groups bound to a carbon skeleton by condensation or addition reactions, e.g. Mannich reaction, addition of ammonia or amines to alkenes or to alkynes or addition of compounds containing an active hydrogen atom to Schiff's bases, quinone imines, or aziranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019243133A 2018-03-26 2019-03-26 Novel compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising same Active AU2019243133B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648381P 2018-03-26 2018-03-26
US62/648,381 2018-03-26
PCT/KR2019/003514 WO2019190172A1 (ko) 2018-03-26 2019-03-26 신규한 화합물 및 이를 포함하는 비만 또는 대사증후군의 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
AU2019243133A1 AU2019243133A1 (en) 2020-10-08
AU2019243133B2 true AU2019243133B2 (en) 2021-03-04

Family

ID=68060316

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019243133A Active AU2019243133B2 (en) 2018-03-26 2019-03-26 Novel compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising same

Country Status (8)

Country Link
US (1) US12065394B2 (enExample)
EP (1) EP3778555A4 (enExample)
JP (1) JP7029213B2 (enExample)
KR (1) KR102054399B1 (enExample)
CN (1) CN112105598B (enExample)
AU (1) AU2019243133B2 (enExample)
TW (1) TWI717712B (enExample)
WO (1) WO2019190172A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666661B2 (en) 2018-03-23 2023-06-06 The Regents Of The University Of California Methods and compounds for targeted autophagy
US12383624B2 (en) 2018-07-24 2025-08-12 Seoul National University R&Db Foundation Cargo delivery system and composition comprising the same
EP3828162B1 (en) 2018-07-24 2025-07-09 Autotac Inc. Novel p62 ligand compound, and composition for preventing, ameliorating, or treating proteinopathies comprising the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022919A1 (en) * 2011-08-08 2013-02-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69227596T2 (de) 1991-10-04 1999-04-08 Taisho Pharmaceutical Co., Ltd., Tokio/Tokyo Alkoxyphenylalkylaminderivat
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
JP3421702B2 (ja) * 1993-03-26 2003-06-30 大正製薬株式会社 シグマ受容体拮抗薬
US6462092B1 (en) 1999-09-23 2002-10-08 G.D. Searle & Co. Use of substituted N, N-disubstituted reverse aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
WO2008011072A2 (en) 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
KR101594168B1 (ko) * 2013-10-02 2016-02-15 서울대학교산학협력단 p62의 ZZ 영역에 의해 매개되는 자가포식 조절 방법 및 그 용도
US10759739B2 (en) * 2015-06-11 2020-09-01 University of Pittsburgh—of the Commonwealth System of Higher Education P62-ZZ small molecule modulators
KR101731908B1 (ko) * 2015-08-18 2017-05-11 서울대학교산학협력단 p62 ZZ 도메인에 결합하는 리간드 또는 아르기닌화된 BiP에 의해 매개되는 오토파지 활성을 통한 신경변성 질환 예방 및 치료

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022919A1 (en) * 2011-08-08 2013-02-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor

Also Published As

Publication number Publication date
WO2019190172A1 (ko) 2019-10-03
TWI717712B (zh) 2021-02-01
US12065394B2 (en) 2024-08-20
KR102054399B1 (ko) 2019-12-10
AU2019243133A1 (en) 2020-10-08
EP3778555A1 (en) 2021-02-17
CN112105598B (zh) 2023-06-27
EP3778555A4 (en) 2022-03-02
US20210024454A1 (en) 2021-01-28
CN112105598A (zh) 2020-12-18
JP2021517171A (ja) 2021-07-15
TW201940461A (zh) 2019-10-16
JP7029213B2 (ja) 2022-03-03
KR20190112673A (ko) 2019-10-07

Similar Documents

Publication Publication Date Title
AU2019243133B2 (en) Novel compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising same
KR900001511B1 (ko) 카테콜 유도체 및 그것을 함유하는 중추신경계 퇴행성질환의 진행방지 및 치료제
CN112654616B (zh) 3-芳氧基-3-芳香基-丙胺类化合物及其用途
CA2855759C (en) Tricyclic compounds, compositions comprising them and uses thereof
US8580848B2 (en) Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof
CA2158910C (en) B3-adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
JP2021534248A (ja) ３−アリールオキシル−３−５員ヘテロアリール−プロピルアミン化合物およびその使用
KR20230003981A (ko) DYRK1 억제제인 피롤로[3,2-c]피리딘 유도체 및 이의 용도
US11046684B2 (en) Compound for selectively inhibiting kinase and use thereof
JP2013516458A (ja) ５−ｈｔ６受容体リガンドとしてのスルホン化合物
JP2020502167A (ja) ピリジン系化合物を有効成分として含有するｄｙｒｋ関連疾患の予防又は治療用薬学的組成物
JP5957452B2 (ja) 肝臓、肺の障害、糖尿病合併症および心血管疾患の処置のためのジフェニルエーテル化合物
JPWO2005079845A1 (ja) 片頭痛予防薬
KR101716560B1 (ko) 페녹시아크릴 유도체 및 이의 용도
KR102847693B1 (ko) 옥사디아졸 유도체를 포함하는 비만의 예방 또는 치료용 조성물
KR102290603B1 (ko) 신규한 리포익산-헤테로사이클 싸이오아세탈 화합물 및 그의 용도
WO2018199562A1 (ko) 신규 화합물 2-아미노-2-(1-(2-(2-히드록시에톡시)에틸)-1h-1，2,3-트리아졸- 4-일)프로판 -1,3-디올 유도체 및 이의 용도
CN110117302B (zh) 神经退行性疾病的治疗药物及其应用
KR102233120B1 (ko) 신규한 파에오놀-트립타민 화합물 및 그의 용도
RU2799454C2 (ru) Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение
KR20250083163A (ko) 신규 화합물 및 이를 포함하는 안질환 예방 또는 치료용 조성물
CN120570882A (zh) 代谢功能障碍相关的脂肪性肝炎治疗药物
JP2024521452A (ja) 新規なインドール誘導体及びその終末糖化産物に関連する疾患の治療用途
KR101653727B1 (ko) 메리디아닌 c 유도체를 유효성분으로 포함하는 항 비만용 조성물
US20200308192A1 (en) Novel thiazolo[5,4-d]pyrimidine derivatives as inverse agonists of a2a adenosine receptors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Free format text: FORMER OWNER(S): PROTECH CO., LTD.